TGTX · TG Therapeutics, Inc. · Stock research

Current Thesis

TG Therapeutics is a profitable, commercial-stage anti-CD20 franchise the market repriced hard in June for a second act. BRIUMVI (ublituximab-xiiy), the approved relapsing-MS therapy, posted Q1 2026 US net product revenue of $194.8M (+63% YoY) and drove the second FY2026 guidance raise this year — total global revenue to ~$925M, US BRIUMVI net to $885–900M, up from the February guide of $825–850M. The June 9 2026 topline myasthenia-gravis Phase 1 read added a credible second large indication and the stock went near-vertical, from ~$42 on June 9 to a 52-week high of $54.07, closing ~$53 on June 18 (+26% in seven sessions). Six weeks on, the mania has unwound: RSI has bled from a blow-off near 94 into the high-70s and lower, with price consolidating in the low-$50s. What kept the tape from rolling over is fresh sell-side confirmation — HC Wainwright reiterated Buy and lifted its target to $77 on July 13, well above spot. The narrative now reloads into the next dated event: the Q2 2026 print, which has rotated inside the 30-day window at roughly early August. That print — US BRIUMVI net versus the ~$195M Q1 run-rate and the odds of a third guidance raise — decides whether the trend re-accelerates or the low-$50s mark a post-catalyst top. A fresh entry here buys an extended name into a binary, not a clean base.

Bullish and bearish views on TG Therapeutics, Inc.

The model's bull view on TG Therapeutics, Inc. (TGTX), in brief: Commercial acceleration is real. Q1 2026 US BRIUMVI net $194.8M (+63% YoY); total global revenue ~$205M; net income $19.8M (reported ~May 2026). Profitability is scarce in this cohort. Guidance raised twice in one year. FY2026 total global revenue lifted to ~$925M and US BRIUMVI… The bear view: Extended and post-catalyst. The +26% June move ran on the MG print and the second guide raise, both now in the tape; the stock cleared the ~$46–48 median target on that run and has spent July consolidating rather than extending. Wide target dispersion. HC Wainwright's $77 (July… Both cases follow in full.

Bull Case

• Commercial acceleration is real. Q1 2026 US BRIUMVI net $194.8M (+63% YoY); total global revenue ~$205M; net income $19.8M (reported ~May 2026). Profitability is scarce in this cohort.
• Guidance raised twice in one year. FY2026 total global revenue lifted to ~$925M and US BRIUMVI net to $885–900M versus the February 2026 guide of $825–850M — management keeps chasing its own numbers higher, framing a possible third raise on the ~August Q2 call.
• Sell-side chasing higher. HC Wainwright maintained Buy and raised its target to $77 on July 13 2026 — a Street number now well above the low-$50s, confirming the June move rather than capping it.
• Self-funding growth. The Q1 2026 update (reported ~May) flagged additional non-dilutive financing plus an expanded buyback — no equity-dilution overhang typical of the sector.
• Second indication with real signal. The June 9 2026 Phase 1 in AChR-antibody-positive MG (n=11): 82% hit the MG-ADL minimal clinically important difference by Week 24, a 4.6-point mean MG-ADL improvement, 30-day median time to response, safety consistent with IV BRIUMVI in MS.
• Differentiated registration path. The ~120-patient Phase 2 initiated June 9 2026 uses efgartigimod induction → BRIUMVI maintenance, targeting the treatment-burden gap in chronic FcRn therapy — a combination competitors are not running.
• Convenience expansion live. Subcutaneous BRIUMVI for MS completed Phase 3 enrollment with positive SC Phase 1 PK/PD already reported (per the Q1/June updates); a clean readout lets BRIUMVI contest Kesimpta on dosing convenience.
• Squeeze fuel. ~23.7M shares short, ~19.5% of float, ~12.8 days to cover as of mid-June 2026 — sustained good news forces covering into a thin tape.

Bear Case

• Extended and post-catalyst. The +26% June move ran on the MG print and the second guide raise, both now in the tape; the stock cleared the ~$46–48 median target on that run and has spent July consolidating rather than extending.
• Wide target dispersion. HC Wainwright's $77 (July 13 2026) sits far above a Street where Goldman holds at $41 and JPMorgan trimmed its target earlier — the range is wide and the median remains near or below spot.
• Earnings binary into the window. Q2 2026 results land around early August.
• MG is years and a controlled trial away. The June 9 Phase 1 was n=11, open-label, uncontrolled; the registration-directed ~120-patient Phase 2 is only just enrolling. Real MG revenue is a long-dated option, absent from any 2026–2027 model.
• Next hard binary is far out. SC BRIUMVI MS Phase 3 topline (Week-24 exposure non-inferiority) is not expected until YE2026/Q1 2027 — nothing dated bridges the gap after the Q2 print except news flow.
• Squeeze cuts both ways. The ~19.5% short interest (mid-June 2026) that fuels covering on good news re-pressures the stock on any momentum stall or in-line print.

Setup & Price Structure

The June 9 MG print launched a ~+26% impulse from ~$42 to a 52-week high of $54.07, closing ~$53 on June 18, with RSI spiking to a blow-off near 94 — the highest-risk point to chase. The tape has since worked that off: RSI unwound to the high-70s and then lower while price held a low-$50s consolidation through July instead of surrendering the breakout. The reference structure is the ~$46–48 shelf — the old median-target zone and the June breakout-retest level. Holding above it keeps the post-MG range intact; a weekly close back below $46 puts price inside the pre-MG range and negates the June move. HC Wainwright's July 13 lift to $77 reset the upside reference well above spot, but between the low-$50s and that number there is no established base — the stock is mid-range, not on a fresh breakout, and the next real trigger is the Q2 print. Entering here means paying for extension ahead of a binary; a constructive setup asks for price holding the $46–48 shelf or a clean post-earnings base before chasing the highs into thinning summer news flow.

Catalyst Calendar (next 30 days)

• ~2026-08-05 (est.) — Q2 2026 earnings. The near-term binary, now inside the window. Watch US BRIUMVI net versus the ~$195M Q1 run-rate, gross-to-net trajectory, and whether management raises FY2026 guidance a third time (current ~$925M global / $885–900M US BRIUMVI net). Binary risk climbs as the date nears; a print inside three trading days argues for standing aside on fresh entries.
• Date TBD — full MG Phase 1 dataset at a medical meeting. The June 9 topline still lacks a full-data presentation; a scheduled congress slot would be an incremental catalyst.
• YE2026 / Q1 2027 (outside window) — SC BRIUMVI MS Phase 3 topline. The next true clinical binary (Week-24 exposure non-inferiority); nothing dated inside 30 days beyond the Q2 print.

Elapsed catalysts

• 2026-07-13 (in the tape) — HC Wainwright reiterated Buy, target to $77. Fresh sell-side confirmation; watch for follow-on target revisions from Goldman ($41) and JPMorgan (recent trim) into the print. (passed 20d ago)

What Would Change Our Mind

A weekly close below $46 breaks the June breakout-retest structure and returns price to the pre-MG range, ending the reprice leg — the primary invalidation. A theme roll to SATURATED — the June news flow fully bled out and no new dated catalyst replacing the Q2 print before YE2026 — is the slower version of the same erosion. On the upside, a beat-and-raise Q2 print with a third guidance lift and a US net well above run-rate would confirm the narrative is re-accelerating rather than maturing, reframing the low-$50s consolidation as a base and putting the $77 target reference back in play.

Correlation Notes

TGTX trades with the commercial-stage neuro-immunology and anti-CD20 / B-cell-depletion complex — read-through from Roche's Ocrevus (including its SC/high-dose franchise), Novartis's Kesimpta, and argenx's FcRn platform (efgartigimod), the last directly relevant given the June 9 Phase 2 combination design. As a profitable specialty-biotech name it is less rate-sensitive than pre-revenue peers but still moves with the broad biotech tape (XBI/IBB) and the risk regime; a factor rotation out of high-beta biotech pressures the whole immunology cluster regardless of company news. Squeeze mechanics (~19.5% short interest, mid-June 2026) amplify moves in both directions relative to fundamentals, so single-name volatility can decouple from the group around the Q2 print.